ANTI-TUMOR COMBINATION THERAPY COMPRISING ANTI-CD19 ANTIBODY AND POLYPEPTIDES BLOCKING THE SIRPΑ-CD47 INNATE IMMUNE CHECKPOINT

摘要

The present disclosure is directed to a combination therapy comprising an antibody or antibody fragment specific for CD19 and a polypeptide that blocks the SIRPα-CD47 innate immune checkpoint for use in the treatment of cancer, in particular hematological cancer such as leukemia or lymphoma.